Key result
TEVAR shows evolving use for thoracic aortic disease, but long-term comparative outcomes remain unproven.
Answers are grounded in this paper and cite their sources.
Following the first reported case of thoracic endovascular aortic repair (TEVAR) in 1987, there has been rapid technological development and widespread uptake of this approach for thoracic aortic disease. TEVAR has particular advantages for acute thoracic syndromes and there is continuing development of TEVAR for use in the elective situation. This is still a young technology and many unknowns remain, including long-term outcomes and the relative advantages and disadvantages versus both conservative treatment and open surgical repair. The current uses of TEVAR in the treatment of aortic dissection, thoracic aortic aneurysm, penetrating aortic ulcer and trauma are discussed.
No takes yet. Share an insight, caveat, or question.
Bicknell et al. (2015) conducted a review in Thoracic aortic disease. Thoracic endovascular aortic repair (TEVAR) vs. Conservative treatment and open surgical repair was evaluated. Thoracic endovascular aortic repair is an evolving treatment for thoracic aortic disease, though its long-term outcomes compared to conservative or open surgery remain unknown.
Synapse has enriched 10 related papers. Consider them for comparative context: